Last Updated : April 11, 2013
Details
FilesGeneric Name:
Everolimus
Project Status:
Complete
Therapeutic Area:
Advanced Breast Cancer
Manufacturer:
Novartis Pharmaceuticals Canada Inc.
Brand Name:
Afinitor
Project Line:
Reimbursement Review
Project Number:
PC0014-000
Performance Metric:
N/A — Predated performance metrics
Strength:
2.5 mg, 5mg and 10 mg
Tumour Type:
Breast
Indications:
Advanced Breast Cancer
Funding Request:
For treatment of post menopausal women with hormone receptor-positive advanced breast cancer in combination with exemestane, after progression or recurrence (failure) on NSAI therapy.
Review Status:
Complete
Pre Noc Submission:
Yes
Sponsor:
Novartis Pharmaceuticals Canada Inc.
Submission Date:
Submission Deemed Complete:
Prioritization Requested:
Not Requested
Stakeholder Input Deadline ‡:
Check-point meeting:
pERC Meeting:
Initial Recommendation Issued:
Feedback Deadline ‡:
Notification to Implement Issued:
Recommendation Type:
Reimburse with clinical criteria and/or conditions
pERC Meeting:
Final Recommendation Issued:
Files
‡ Patient Advocacy Groups (or individual patients and caregivers when there is no patient group) and Clinicians who are registered with pCODR are eligible to provide Input and Feedback. Deadlines for Input and Feedback are by the end of the pCODR business day (5P.M. Eastern Time) of the date noted.
Last Updated : April 11, 2013